Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)-Reference-Cited by-同舟云学术

Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM)

Published:2020-03 Issue: Volume:127 Page:173-182
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Holmsten Karin,Jensen Niels Viggo,Mouritsen Lene Sonne,Jonsson Erika,Mellnert Camilla,Agerbæk Mads,Nilsson Cecilia,Moe Mette,Carus Andreas,Öfverholm Elisabeth,Lahdenperä Outi,Brandberg Yvonne^ORCID,Johansson Hemming,Hellström Mats,Maase Hans von der,Pappot Helle,Ullén Anders

Funder

Stockholms Läns Landsting

Cancerföreningen i Stockholm

Cancerfonden

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference25 articles.

1. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse;Sternberg;Cancer,1989

2. Randomized Phase III Trial of High–Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924

3. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study;von der Maase;J Clin Oncol : Off j Am Soc Clin Oncol,2000